our capabilities

Uniquely integrated formulation, device and development capabilities

We effectively integrate all technologies and disciplines required to deliver an inhaled product.

Learn more

Investors

Share price

Learn more

Latest results

View archive

See all

ANNUAL REPORT 2018

AR18_mockup.png

Annual Report and Accounts for the year ended 31 December 2018

Read more
Vectura news
Mar 26, 2019, 7:05 AM
Vectura reports strong 2018 financial and operational performance
Jan 3, 2019, 6:48 AM
Pre-close trading update confirms good progress against 2018 goals
Nov 7, 2018, 6:07 PM
Global agreement with Hikma to develop generic versions of GSK’s Ellipta® portfolio
Sep 26, 2018, 2:45 PM
Rising to the challenge of developing inhaled generic medicines
Read more
Investment case
1

Differentiated inhalation development capabilities

2

In-market product cash flow generation

3

Focused R&D strategy with pipeline progression and partnering potential

4

Focus on Operational Excellence

5

Strong cash flow generation and capital discipline

Learn more